STUDIES IN THYROID DISEASE

两种形式的辅助治疗旨在提高I- 131甲状腺癌的放射治疗正在研究之中。 第一个是锂离子， 其用于延长I-131在癌症中的保留。 初步 以往的年度报告已介绍了调查结果。 二是 多柔比星（阿霉素）作为放射增敏剂的用途。 评价 其有效性，我们已经开始随机研究高危甲状腺 接受标准I-131治疗的癌症患者， 在每次I-131前30 min给予小剂量阿霉素（10 mg/m2） 治疗剂量 据我们所知，这是第一次尝试随机化 使用I-131的甲状腺癌治疗方案中的患者。 其他I-131全身扫描阴性但升高的患者 血液中的甲状腺球蛋白浓度给予I-131治疗， 试图通过治疗后扫描定位癌症。 大多数患者 已经被发现有积极的治疗后扫描， 评估治疗的可能有益效果。

Two forms of adjuvant therapy designed to improve the effectiveness of I- 131 radiation in thyroid cancer are under study. The first is lithium ion, which is used to prolong the retention of I-131 in the cancer. Preliminary findings have been described in previous annual reports. The second is the use of doxorubicin (adriamycin) as a radiosensitizing agent. To evaluate its effectiveness, we have begun to randomized study of high-risk thyroid cancer patients who receive standard I-131 therapy with or without the administration of low-dose adriamycin (10mg/m2) 30 min preceding each I-131 treatment dose. To our knowledge, this is the first attempt to randomize patients in a therapy protocol for thyroid cancer employing I-131. Other patients with negative I-131 whole body scans but elevated concentration of thyroglobulin in blood are given I-131 therapy in an attempt to localize the cancer by post-therapy scanning. Most patients have been found to have positive post-therapy scans and they are under evaluation for possible beneficial effects of the therapy.